A method that emerged from a UW–Madison spinoff company is in clinical trials in Europe, Asia and the United States against the infection, which can destroy the liver.
Mitochondrial diseases strike about 1 in 4,000 people and there are currently no licensed therapies available beyond treatments with vitamins and supplements.
With a unique approach that draws on 3-D printing technologies, a team of UW–Madison researchers is developing new tools for understanding how ovarian cancer develops in women.
The findings provide the foundation for future antiviral drug and vaccine development against rhinovirus C.
The company makes cutting-edge products based on discoveries by three UW scientists for delivering DNA and RNA into cells.
Lynx Biosciences is developing technology to choose the drug most likely to benefit a blood cancer patient by analyzing how the tumor cells respond.
The artificial eyes created by UW–Madison engineers could help search-and-rescue robots or surgical scopes make dim surroundings seem bright as day.